ClexBio
Most cell and stem cell therapies fail beyond blood cancers because delivery cannot preserve function or safety in solid tissue. ClexBio solves this with a universal platform for solid tissue and organ replacement that mimics biology, prevents immune rejection, and enables durable persistence. This unlocks regenerative therapies for liver failure, type 1 diabetes, and heart disease. Backed by top investors, we are raising $10M toward IND studies and pharma partnerships.
Category
Emerging biotech company
Title of the presentation
Powering the scalable era of tissue-based stem cell therapy
Speaker information
| Name | Position | Institution |
|---|---|---|
| Armend Hati | CEO | ClexBio |
